Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.32 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.32 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496187 | 0.87 | LPAR1 (0.36) | LPAR1LPAR3LPAR2NR3C2P2RX7 | |
| SCHEMBL11896354 | 0.86 | KMT2A (0.37) | KMT2AALDH1A1 | |
| SCHEMBL16496719 | 0.86 | TSHR (0.38) | LPAR1LPAR3P2RX7SLC26A6ALDH1A1 | |
| SCHEMBL2839139 | 0.85 | CTSK (0.37) | LPAR1LPAR3LPAR2NR3C2NR3C1 | |
| SCHEMBL2836559 | 0.85 | ALDH1A1 (0.39) | LPAR1LPAR3LPAR2P2RX7SLC26A6 | |
| SCHEMBL16496544 | 0.85 | SLC26A6 (0.35) | LPAR1LPAR3P2RX7SLC26A6MAPT | |
| SCHEMBL16496520 | 0.82 | TRPA1 (0.46) | MAPT | |
| SCHEMBL2837640 | 0.80 | MAPT (0.35) | P2RX7SLC26A6KMT2AALDH1A1MAPT | |
| SCHEMBL16060874 | 0.76 | LPAR1 (0.42) | LPAR1LPAR3LPAR2P2RX7SLC26A6 | |
| SCHEMBL16060372 | 0.75 | LPAR1 (0.40) | LPAR1LPAR3LPAR2NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358688-B1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-8440707-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | claimed |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20150164874-A1 | PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS | INTERMUNE, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2358688-B1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130150426-A1 | METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS | INTERMUNE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8440707-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885 |
| US-20150164874-A1 | PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS | FIBP, PTGFR, MMP1 | LPAR1 1534/4885LPAR3 747/4885LPAR2 1143/4885 |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885 |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.